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We are happy to see Li et al's [1] report in the 2011 issue of the
Taiwanese Journal of Obstetrics and Gynecology, which provided a
good suggestion for our clinical practice. Dr. Li et al [1] suggested
that the combination of mifepristone and misoprostol was safe
and effective for ﬁrst-trimester pregnancy termination. The
above-mentioned suggestion is worthy of being announced again,
since much evidence supported that concurrent mifepristone and
misoprostol is more effective than prostaglandin derivatives alone
for second- or third-trimester abortion. In fact, two other published
articles in the same year (2011) in the Taiwanese Journal of Obstet-
rics and Gynecology also highlighted the beneﬁts of the combined
therapy compared with each alone [2,3].
Mifepristone (RU 486) is a 19-norsteroid that speciﬁcally blocks
receptors for progesterone and glucosteroids and a well-known se-
lective progesterone receptor modulator. Although the action of se-
lective progesterone receptor modulators on progesterone
receptors might be agonist and antagonist [4,5], mifepristone
showed a potent antiprogestogenic effect for pregnancy, acting as
a competitive inhibitor of the progesterone receptor and used as
a pretreatment 24e48 hours before inducing ﬁrst-trimester abor-
tion with a prostaglandin analog. Mifepristone may sensitize the
uterine myometrium to prostaglandin; decrease the contractility
threshold of the uterus, and ripen the cervix facilitating abortion;
and oxytocin is released physiologically by the posterior pituitary,
stimulating uterine contractions. Misoprostol, a synthetic prosta-
glandin E1 analog, was initially used to prevent peptic ulcers.
With its cervical-ripening and uterotonic properties, misoprostol
became one of the most useful drugs in pregnancy termination
and labor induction. Misoprostol has proved effective for preg-
nancy termination at various gestational ages, cervical ripening,
labor-induction in term-pregnancies, incomplete-abortion treat-
ment, and postpartum hemorrhage management. Therefore, the
recently published articles addressing the topic of the misoprostol
administration route and dose interval between mifepristone and
misoprostol might further improve our clinical practice.
The ﬁrst study from a Hoopmann et al's [6] retrospective study,
which investigated the effect of mifepristone before administering
a prostaglandin derivative on induction time, showed that 333 pa-
tients hadmedically indicated terminations after the ﬁrst trimester,
in which the prostaglandin derivatives were administered with or
without pretreatment with 600 mg mifepristone. The authors
found that the induction interval shortened signiﬁcantly by pre-
treatment with mifepristone. The combination of mifepristone
and a prostaglandin derivative was the most effective regimen for
medical pregnancy termination.http://dx.doi.org/10.1016/j.tjog.2015.06.006
1028-4559/Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. PublishedThe second study fromDickinson et al's [7] prospective random-
ized trial of medical abortion with misoprostol after mifepristone
priming at 14e24 weeks of gestation, showed that 302 patients
received 200 mg mifepristone orally, followed by an 800-mg
vaginal loading misoprostol dose 24e48 hours later. The patients
were then randomized to receive additional 400-mg misoprostol
doses orally every 3 hours, vaginally every 4 hours, or sublingually
every 3 hours. The conclusion showed that vaginal or sublingual
misoprostol after a vaginal loading dose in second-trimester med-
ical abortionwith mifepristone priming is associated with a shorter
time to pregnancy termination compared with an oral regimen.
The combination of mifepristone and misoprostol for second-
trimester termination has a shorter induction time and lowermiso-
prostol dose compared withmisoprostol alone. Both sublingual and
vaginal routes of misoprostol administration resulted in a shorter
abortion duration compared with that using the oral route. The dif-
ferences in duration or side effects between sublingual and vaginal
routes of misoprostol administrationwere not signiﬁcant [8]. How-
ever, sublingual administration may be preferred by patients over
vaginal administration due to ease of use [7].
Taken together, we found that the combination of mifepristone
and misoprostol vaginally followed by vaginal or sublingual miso-
prostol may be effective and preferred for second-trimester preg-
nancy termination. We highly recommend that since women
with no previous deliveries or increased gestational age (> 16
weeks) may have an increased failure rate of medical termination,
a longer interval time (41e45 hours) between mifepristone and
misoprostol may be more suitable for these groups [9].
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